“We look forward to applying E-602 to treat diseases that align with its pharmacological characteristics, and advancing our next-generation EAGLE molecules that have a longer half-life sialidase ...

The first-in-class human sialidase enzyme therapeutic E-602 is based on the company’s oncology platform, Enzyme Antibody Glyco-Ligand Editing (EAGLE). The Glycan-Mediated Immune Regulation (GLIMMER-01 ...

[11–13] Testing for Sialidase Activity The BVBlue® (Gryphus Diagnostics, AL, USA) system is a chromogenic diagnostic test based on the presence of elevated sialidase enzyme activity in vaginal ...

Palleon Pharmaceuticals has reported the outcomes from its Phase I/II study of E-602 along with programmed death (PD)-1 ...

The first-in-class human sialidase enzyme therapeutic E-602 is based on the company’s oncology platform, Enzyme Antibody Glyco-Ligand Editing (EAGLE). The Glycan-Mediated Immune Regulation ...

Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21231, United States ...